Literature DB >> 28393707

Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure.

Sheng Kang1, Lie-Ying Fan2, Ming Chen3, Jue Li4, Zhong-Min Liu5.   

Abstract

OBJECTIVE: Excessive activated proinflammatory cytokines may promote extracellular matrix alterations which induce adverse left ventricular remodeling in systolic heart failure (SHF). We sought to identify whether high-sensitivity C-reactive protein (hsCRP) levels were independently associated with SHF.
METHODS: In our retrospective case-control study, 2236 subjects were included, and 260 patients had SHF. Blood sample collection, clinical laboratory tests, electrocardiogram and echocardiography examinations were performed. The questionnaires were completed by professional interviews.
RESULTS: In 2236 subjects, the prevalence rate of SHF were 1.7, 1.8, 8.4 and 32.6% between hsCRP concentrations (<1 mg/L, ≥1 to <3 mg/L, ≥3 to <10 mg/L and ≥10 mg/L, respectively) (p=0.000). hsCRP concentrations (<1 mg/L, ≥1 to <3 mg/L, ≥3 to <10 mg/L and ≥10 mg/L) were associated in a linear trend with N-terminal pro-brain natriuretic peptide (NT-proBNP, p=0.000) and left ventricular ejection fraction (LVEF, p=0.000). hsCRP was also significantly related to NT-proBNP, LVEF and SHF (r=0.232, p=0.000; r=-0.358, p=0.000 and r=0.413, p=0.000, respectively). In logistic regression model, after adjusting for heart failure risk factors, compared with the low concentration of hsCRP (<1 mg/L), the high concentration of hsCRP (≥10 mg/L) was significantly independently associated with SHF (odds ratio = 10.78 [1.303 to 89.10], p=0.027).
CONCLUSION: Low to high concentration of hsCRP showed a linear trend association with SHF. A high concentration of hsCRP was independently associated with SHF. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  High-sensitivity C-reactive protein; fasting blood sugar; systolic heart failure; total cholesterol

Mesh:

Substances:

Year:  2017        PMID: 28393707     DOI: 10.2174/1570161115666170404121619

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  5 in total

1.  Specific biomarkers of myocardial inflammation and remodeling processes as predictors of mortality in high-risk patients undergoing percutaneous mitral valve repair (MitraClip).

Authors:  Oliver Dörr; Claudia Walther; Christoph Liebetrau; Till Keller; Hannes Tabert; Niklas Boeder; Matthias Bayer; Pascal Bauer; Helge Möllmann; Luise Gaede; Christian Troidl; Sandra Voss; Timm Bauer; Christian W Hamm; Holger Nef
Journal:  Clin Cardiol       Date:  2018-04-17       Impact factor: 2.882

2.  The effects of levosimendan use on high-sensitivity C-reactive protein in patients with decompensated heart failure.

Authors:  Hasan Korkmaz; Mücahid Yilmaz
Journal:  Arch Med Sci Atheroscler Dis       Date:  2019-07-22

Review 3.  New aspects in cardiorenal syndrome and HFpEF.

Authors:  Ana Belén Méndez; Maria Antonieta Azancot; Aleix Olivella; María José Soler
Journal:  Clin Kidney J       Date:  2022-05-06

Review 4.  Biomarkers in Cardiorenal Syndromes.

Authors:  Shihui Fu; Shaopan Zhao; Ping Ye; Leiming Luo
Journal:  Biomed Res Int       Date:  2018-03-05       Impact factor: 3.411

5.  Residual inflammatory risk in coronary heart disease: incidence of elevated high-sensitive CRP in a real-world cohort.

Authors:  Alexander Peikert; Klaus Kaier; Julian Merz; Lucas Manhart; Ibrahim Schäfer; Ingo Hilgendorf; Philipp Hehn; Dennis Wolf; Florian Willecke; Xia Sheng; Andreas Clemens; Manfred Zehender; Constantin von Zur Mühlen; Christoph Bode; Andreas Zirlik; Peter Stachon
Journal:  Clin Res Cardiol       Date:  2019-07-19       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.